BRIEF-Halozyme Therapeutics Q4 Operating Expenses USD 122.507 Million

Reuters
19 Feb
BRIEF-Halozyme <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q4 Operating Expenses USD 122.507 Million

Feb 18 (Reuters) - Halozyme Therapeutics Q4 operating income USD 175.501 million.

  • Q4 net income USD 137.012 million
  • Q4 pretax profit USD 178.214 million
  • outlook FY revenue USD 1,150-1,225 million

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10